156 related articles for article (PubMed ID: 37204752)
1. Protocol for the Investigation of Plasma and Whole Blood Clot Property of Fibrin Fiber Thickness Using Scanning Electron Microscopy.
Cai T; McCafferty C; Van Den Helm S; Letunica N; Attard C; Monagle P; Ignjatovic V
Methods Mol Biol; 2023; 2663():775-786. PubMed ID: 37204752
[TBL] [Abstract][Full Text] [Related]
2. Automated Fiber Diameter and Porosity Measurements of Plasma Clots in Scanning Electron Microscopy Images.
Daraei A; Pieters M; Baker SR; de Lange-Loots Z; Siniarski A; Litvinov RI; Veen CSB; de Maat MPM; Weisel JW; Ariëns RAS; Guthold M
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680169
[TBL] [Abstract][Full Text] [Related]
3. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen.
Hugenholtz GC; Macrae F; Adelmeijer J; Dulfer S; Porte RJ; Lisman T; Ariëns RA
J Thromb Haemost; 2016 May; 14(5):1054-66. PubMed ID: 26833718
[TBL] [Abstract][Full Text] [Related]
4. Interpretation and Validation of Maximum Absorbance Data Obtained from Turbidimetry Analysis of Plasma Clots.
Pieters M; Guthold M; Nunes CM; de Lange Z
Thromb Haemost; 2020 Jan; 120(1):44-54. PubMed ID: 31752041
[TBL] [Abstract][Full Text] [Related]
5. Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism.
Martinez MR; Cuker A; Mills AM; Crichlow A; Lightfoot RT; Chernysh IN; Nagaswami C; Weisel JW; Ischiropoulos H
Am J Physiol Lung Cell Mol Physiol; 2014 Mar; 306(5):L397-404. PubMed ID: 24414255
[TBL] [Abstract][Full Text] [Related]
6. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
7. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
8. Fibrin clot structure in patients with end-stage renal disease.
Sjøland JA; Sidelmann JJ; Brabrand M; Pedersen RS; Pedersen JH; Esbensen K; Standeven KF; Ariëns RA; Gram J
Thromb Haemost; 2007 Aug; 98(2):339-45. PubMed ID: 17721616
[TBL] [Abstract][Full Text] [Related]
9. Decreased fibrinolytic potential and morphological changes of fibrin structure in dermatitis herpetiformis.
Görög A; Németh K; Szabó L; Mayer B; Silló P; Kolev K; Kárpáti S
J Dermatol Sci; 2016 Oct; 84(1):17-23. PubMed ID: 27440075
[TBL] [Abstract][Full Text] [Related]
10. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
[TBL] [Abstract][Full Text] [Related]
11. Structure of fibrin: impact on clot stability.
Weisel JW
J Thromb Haemost; 2007 Jul; 5 Suppl 1():116-24. PubMed ID: 17635717
[TBL] [Abstract][Full Text] [Related]
12. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
13. Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults.
Ignjatovic V; Pelkmans L; Kelchtermans H; Al Dieri R; Hemker C; Kremers R; Bloemen S; Karlaftis V; Attard C; de Laat B; Monagle P
Thromb Res; 2015 Dec; 136(6):1303-9. PubMed ID: 26522267
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of fibrinogen Bicêtre II: a gamma 308 Asn-->Lys mutation located near the fibrin D:D interaction sites.
Marchi RC; Carvajal Z; Boyer-Neumann C; Anglés-Cano E; Weisel JW
Blood Coagul Fibrinolysis; 2006 Apr; 17(3):193-201. PubMed ID: 16575257
[TBL] [Abstract][Full Text] [Related]
15. Biomaterial Wettability Affects Fibrin Clot Structure and Fibrinolysis.
Ruhoff AM; Hong JK; Gao L; Singh J; Tran C; Mackie G; Waterhouse A
Adv Healthc Mater; 2021 Oct; 10(20):e2100988. PubMed ID: 34423587
[TBL] [Abstract][Full Text] [Related]
16. Labeling fibrin fibers with beads alter single fibrin fiber lysis, external clot lysis, and produce large fibrin aggregates upon lysis.
Rimi N; Helms CC
Blood Coagul Fibrinolysis; 2022 Oct; 33(7):364-371. PubMed ID: 35834714
[TBL] [Abstract][Full Text] [Related]
17. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
[TBL] [Abstract][Full Text] [Related]
18. The role of activated coagulation factor XII in overall clot stability and fibrinolysis.
Konings J; Hoving LR; Ariëns RS; Hethershaw EL; Ninivaggi M; Hardy LJ; de Laat B; Ten Cate H; Philippou H; Govers-Riemslag JW
Thromb Res; 2015 Aug; 136(2):474-80. PubMed ID: 26153047
[TBL] [Abstract][Full Text] [Related]
19. Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure.
Henderson SJ; Xia J; Wu H; Stafford AR; Leslie BA; Fredenburgh JC; Weitz DA; Weitz JI
Thromb Haemost; 2016 Mar; 115(3):533-42. PubMed ID: 26489782
[TBL] [Abstract][Full Text] [Related]
20. Shear stimulated red blood cell microparticles: Effect on clot structure, flow and fibrinolysis.
Buerck JP; Foster KM; Larson PR; O'Rear EA
Biorheology; 2023; 59(1-2):43-59. PubMed ID: 36970891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
